NASDAQ:RANI • US7530181004
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RANI THERAPEUTICS HOLDINGS-A (RANI).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-20 | Maxim Group | Maintains | Buy -> Buy |
| 2025-05-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-26 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-08-02 | Oppenheimer | Initiate | Outperform |
| 2024-06-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-14 | Maxim Group | Initiate | Buy |
| 2024-06-13 | Rodman & Renshaw | Initiate | Buy |
| 2024-05-09 | BTIG | Maintains | Buy -> Buy |
| 2024-05-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-27 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-03-25 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-06 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-11-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-21 | B of A Securities | Maintains | Buy -> Buy |
| 2023-08-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.028M | 1.633M 58.85% | 6.885M 321.62% | 11.998M 74.26% | 34.638M 188.70% | 65.7M 89.68% | 168.06M 155.80% | 379.12M 125.59% | 577.34M 52.28% | 807.67M 39.90% | ||
| EBITDA YoY % growth | -65.277M -3.78% | -48.572M 25.59% | -37.41M 22.98% | -58.051M -55.18% | -60.954M -5.00% | -33.603M 44.87% | 501.84K 101.49% | 112.16M 22,249.75% | 313.38M 179.40% | 529.44M 68.95% | N/A | |
| EBIT YoY % growth | -66.099M -4.17% | -49.6M 24.96% | -38.31M 22.76% | -39.496M -3.10% | -44.305M -12.18% | -39.915M 9.91% | -19.883M 50.19% | 53.137M 367.25% | 228.51M 330.04% | 399.47M 74.82% | 625.76M 56.65% | |
| Operating Margin | N/A | -4,824.90% | -2,345.99% | -573.65% | -369.27% | -115.23% | -30.26% | 31.62% | 60.27% | 69.19% | 77.48% | |
| EPS YoY % growth | -1.33 -3.91% | -1.06 20.30% | -0.59 44.34% | -0.28 53.32% | -0.29 -4.63% | -0.48 -66.37% | -0.45 5.32% | -0.14 68.54% | 0.64 550.00% | 1.06 65.08% | 1.57 48.08% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 60.59% | -0.10 46.17% | -0.10 15.00% | -0.10 -38.43% | -0.04 52.94% | -0.04 57.89% | -0.05 50.00% | -0.05 47.37% |
| Revenue Q2Q % growth | 2.295M 1,234.30% | 2.295M | 2.295M | 2.295M 57.19% | 4.692M 104.44% | 4.896M 113.33% | 5.304M 131.11% | 5.508M 140.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.099M 32.58% | -9.237M 12.07% | -10.542M -45.26% | -11.525M -35.04% | -7.882M 2.69% | -8.224M 10.96% | -8.91M 15.48% | -9.252M 19.72% |
All data in USD
9 analysts have analysed RANI and the average price target is 8.16 USD. This implies a price increase of 969.32% is expected in the next year compared to the current price of 0.7631.
The consensus EPS estimate for the next earnings of RANI THERAPEUTICS HOLDINGS-A (RANI) is -0.09 USD and the consensus revenue estimate is 2.29M USD.
The consensus rating for RANI THERAPEUTICS HOLDINGS-A (RANI) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.